Status:
COMPLETED
An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Nausea
Vomiting
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This protocol will study an investigational drug treatment plan against standard therapy in the prevention of chemotherapy-induced nausea and vomiting in patients diagnosed with breast cancer who are ...
Eligibility Criteria
Inclusion
- Patient with a diagnosis of breast cancer requiring treatment with non-cisplatin moderately emetogenic chemotherapy.
Exclusion
- Patient has a central nervous system malignancy.
- Patient will receive radiation to the abdomen or pelvis.
Key Trial Info
Start Date :
October 10 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 11 2004
Estimated Enrollment :
866 Patients enrolled
Trial Details
Trial ID
NCT00092183
Start Date
October 10 2002
End Date
February 11 2004
Last Update
May 5 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.